SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?


To: Brian Malloy who wrote (698)4/10/1999 11:26:00 AM
From: blake_paterson  Read Replies (2) | Respond to of 942
 
Brian: On what basis do you presume that the two new glitazones, if approved, will not have similar monitoring guidelines in their initial labeling? Remember that, at 1:50,000 to 1:100,000, hepatic necrosis, if present, won't likely become evident in those compounds until well after market approval and release!

Just my PERSONAL opinion and not that of my employer: disclosure, I work for WLA.

BP